About Biocon Limited

Biocon Limited is a diversified global biopharmaceutical group headquartered in Bengaluru, India, operating across small-molecule generics, biosimilars (through Biocon Biologics), and research & manufacturing services (Syngene), to expand access to affordable, high-quality medicines worldwide. Founded in 1978, Biocon evolved from enzymes to APIs, biosimilars, novel biologics and, most recently, finished dosage formulations. In FY25, Biocon reached over 21 million patients across 120+ countries (Biosimilars 5.8+ million; Generics/APIs 15.4+ million). 

Biocon Biologics’ portfolio includes Ogivri® (bTrastuzumab), Abevmy®/Jobevne™ (bBevacizumab), Fulphila® (bPegfilgrastim), Semglee® (Insulin Glargine), and Yesintek™ (bUstekinumab)—launched in the U.S. in FY25, with additional approvals in the EU/UK and commercialization in Germany and Japan (via partner). In Generics, Biocon entered GLP-1s with Liraglutide in the UK under Liraglutide Biocon (diabetes) and Biolide (weight management), received EU DCP approval, and began commercial supplies from its Cranbury, New Jersey OSD facility.

Biocon Limited’s Business Segments

Generics (Biocon Limited): Manufactures and supplies APIs and finished dosages with strong capabilities in fermentation (notably statins and immunosuppressants) and complex formulations. The commercial strategy combines direct sales and partnerships across the U.S., Europe, and emerging markets.

Biosimilars (Biocon Biologics): A fully integrated global biosimilars business focused on diabetology, oncology, immunology and other chronic diseases, leveraging global-scale manufacturing and a strong pipeline to improve access to advanced biologics .

Research Services (Syngene): Provides integrated research, development, and manufacturing solutions to global pharma and biotech clients; ~400 active clients include 14 of the top 20 global pharma companies, supported by 5,600 scientists.

Industries served by Biocon: Therapeutic areas include diabetes/obesity, cancer, and autoimmune/inflammatory diseases, alongside a broad generics portfolio and end-to-end CRDMO services for life sciences customers .

Biocon Limited Revenue by Industry Vertical (FY25)

• Biosimilars: ₹90,174 million (58%)

• Research Services: ₹36,424 million (23%)

• Generics: ₹30,175 million (19%)

Biocon Limited Revenue by Geography (FY25, revenue from operations)

• United States of America: ₹70,423 million
• European Union (incl. Ireland): ₹38,481 million

• Rest of the world: ₹33,948 million

• India: ₹9,765 million

• Total: ₹152,617 million. 

Biocon Limited Key Management

• Kiran Mazumdar-Shaw, Executive Chairperson (Biocon Limited & Biocon Biologics).

• Siddharth Mittal, Managing Director & CEO, Biocon Limited.

• Shreehas Tambe, CEO & Managing Director, Biocon Biologics

Latest Updates on Biocon Limited

• Product launches/approvals: Biocon Biologics launched Yesintek (bUstekinumab) in the U.S., with approvals also in the EU and UK and commercialization in Germany and Japan; strategic settlements enabled early access across major geographies . In Generics, Biocon launched Liraglutide in the UK as Liraglutide Biocon (diabetes) and Biolide (weight management), received EU DCP approval, and commenced commercial supplies from its oral solid dosage facility in Cranbury, New Jersey. 
• Market traction: U.S. oncology biosimilars saw share gains, with Ogivri’s market share doubling to 26% and Fulphila reaching 30%. In Europe, Ogivri and Abevmy expanded in key markets; insulin franchises maintained mid‑to‑high‑teen shares in U.S. channels .
• Regulatory/manufacturing: U.S. FDA classified sites in India and Malaysia as VAI, supporting U.S. supply; capacity expanded at the insulin facility in Malaysia to meet rising demand .